Global Biosimilars Partnering Terms and Agreements Directory 2020: Access Biosimilars Partnering Deals and Agreements by the Worlds Leading Healthcare Companies
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2020" report has been added to ResearchAndMarkets.com's offering.
The Global Biosimilars Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Report scope
Global Biosimilars Partnering Terms and Agreements 2010 to 2020 includes:
Trends in Biosimilars dealmaking in the biopharma industry since 2010
Analysis of Biosimilars deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Biosimilars deals
Access to over 140 Biosimilars deal records and contract documents where available
The leading Biosimilar deals by value since 2010
Most active Biosimilars dealmakers since 2010
The leading Biosimilars partnering resources
In Global Biosimilars Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active Biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Biosimilars partnering by industry sector
2.7. Deal terms for Biosimilars partnering
2.7.1 Biosimilars partnering headline values
2.7.2 Biosimilars deal upfront payments
2.7.3 Biosimilars deal milestone payments
2.7.4 Biosimilars royalty rates
2.8. The anatomy of an Biosimilars deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals
Chapter 3 - Leading Biosimilars deals
3.1. Introduction
3.2. Top Biosimilars deals by value
Chapter 4 - Most active Biosimilars dealmakers
4.1. Introduction
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles
Chapter 5 - Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory
Chapter 6 - Biosimilars dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Biosimilars deals by company A-Z
Appendix 2 - Biosimilars deals by stage of development
Appendix 3 - Biosimilars deals by deal type
Appendix 4 - Biosimilars deals by therapy area
Companies Mentioned
3SBio
Abbvie
Abreos Biosciences
Abzena
Accord Healthcare
Aceno Biotherapeutics
AdAlta
Aetos Biologics
AffaMed Therapeutics
Alteogen
Altiora
Alvogen
Alvotech
Amedica
Amgen
Amneal Pharmaceuticals
Back-A-Line
Bacterin International
Baxter International
Bio-Thera Solutions
Biocon
Bio Farma
Biogen
BioSciencesCorp
C-Bridge Capital
Catalent Pharma Solutions
CEA-Leti
Celares
Celltrion
Cipla
CJ Corp
Clinigen
Cobra Biologics
Coherus Biosciences
Cook Pharmica
CR Pharma
Daiichi Sankyo
Diabeloop
Dr. Reddy's Laboratories
Dyadic International
EirGenix
EMD Millipore
Epirus Biopharmaceuticals
Epivax
European Commission
Ewopharma
Fujifilm Kyowa Kirin Biologics
Fuji Pharma
Genentech
Hadasit Medical Research Services and Development
Helvetic Biopharma
Henlius Biotech
Hikma Pharmaceuticals
Hoffmann La Roche
Horizon 2020
Hospira
Ipca Laboratories
Jacobson Pharma
JHL Biotech
Laboratorios Liomont
LABORATORIOS SAVAL
Livzon Mabpharm
Lupin
Mab-Venture Biopharma
Mabion
mAbXience
Merck KGaA
MGC Diagnostics
Mithra Pharmaceuticals
Mitsubishi Chemical
Momenta Pharmaceuticals
Mylan Laboratories
Mylan Pharmaceuticals
NanoLock
NCPC GeneTech
NeuClone
Novo Nordisk
Oncobiologics
Pall Corporation
Pfenex
PharmaPraxis
PlantForm
Polpharma
Premier Inc
Premier Research
Prestige BioPharma
ProBioGen
Qilu Pharmaceutical
QuiaPEG Pharmaceuticals
Ranbaxy Laboratories
Revance Therapeutics
Samsung Bioepis
Sandoz
Sanofi
Selexis
Serum Institute of India
Simcere Pharmaceuticals
STADA Arzneimittel
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Theradiag
TR-Pharm
True Diagnostics
Turgut Ilaclari
UGA Biopharma
Univercells
Walloon Region Investment Fund
Walter and Eliza Hall Institute
Xbrane Bioscience
XL-Protein
YL Biologics
Yoshindo
Zhejiang Hisun Pharmaceutical
Zosano Pharma
For more information about this report visit https://www.researchandmarkets.com/r/hhaijx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900